Art. -Nr.: HY-19940

Olitigaltin

Name: Olitigaltin
Brand: MedChemExpress
SKU: HY-19940
Price: 80.00 USD
Availability: InStock
Rating: 5 (13 reviews)

(Synonyms: TD139; GB0139)

13 Cited Publications

Kundenbewertung

Based on 13 publication(s) in Google Scholar

Olitigaltin (TD139) is a high-affinity Galectin-3 inhibitor with a K_d value of 14 nM. Olitigaltin inhibits the activity of the AKT/β-catenin pathway, induces Apoptosis, and downregulates SREBP1 expression. Olitigaltin enhances the phosphorylation level of ERK. Olitigaltin alleviates bleomycin (HY-17565A)-induced advanced pulmonary fibrosis in mice. Olitigaltin delays the onset of diabetes, and improves glucose tolerance and serum insulin levels. Olitigaltin alleviates liver injury. Olitigaltin maintains the structure of hippocampal excitatory synapses, restores γ-wave power in the hippocampal CA1 region, inhibits hippocampal neuroinflammation, and improves cognitive function in neuroinflammation models. Olitigaltin can be used in research related to thyroid cancer, idiopathic pulmonary fibrosis, type 1 diabetes, hepatitis, and cognitive dysfunction induced by neuroinflammation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.74%
CAS. Nr.: 1450824-22-2
Formel: C₂₈H₃₀F₂N₆O₈S
Molecular Weight:648.64

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Olitigaltin Chemical Structure

CAS. Nr.: 1450824-22-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (13)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[2]

Galectin-3

14 nM (Kd)

Galectin-1

10 nM (Kd)

Alle Galectin Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	IC₅₀	0.3 μM Compound: 6; TD139	Inhibition of moues Gal3-induced hemagglutination using mouse RBC incubated for overnight by hemagglutination assay Inhibition of moues Gal3-induced hemagglutination using mouse RBC incubated for overnight by hemagglutination assay	[PMID: 33988358]
Monocyte	IC₅₀	0.08 μM Compound: 6; TD139	Inhibition of human Gal3-induced chemotaxis using human monocyte incubated for 4 hrs by calcein-AM dye based assay Inhibition of human Gal3-induced chemotaxis using human monocyte incubated for 4 hrs by calcein-AM dye based assay	[PMID: 33988358]

In Vitro

Olitigaltin (10-100 μM; 24-72 h) reduces cell viability in a dose-dependent manner in FTC-133 and 8505C thyroid cancer cells (inducing 41.1-49.7% viability reduction at 100 μM for 72 h) but does not affect viability in Nthy-ori 3-1 thyroid follicular epithelial cells^[1].
Olitigaltin (10-100 μM; 10 days) abrogates the colony-forming ability of FTC-133 and 8505C thyroid cancer cells at 100 μM over 10 days^[1].
Olitigaltin (10-100 μM; 24 h) inhibits migration and invasion in a dose-dependent manner in FTC-133 and 8505C thyroid cancer cells at 10 and 100 μM for 24 h, but stimulates invasion in Nthy-ori 3-1 thyroid follicular epithelial cells at 100 μM for 24 h^[1].
Olitigaltin (10-100 μM; 24 h) induces apoptosis in FTC-133 and 8505C thyroid cancer cells, increasing sub-G1 cell populations to 31.3% and 35.0% respectively at 100 μM for 24 h^[1].
Olitigaltin (10-100 μM; 24 h) modulates key signaling and apoptotic proteins in FTC-133 and 8505C thyroid cancer cells at 10 and 100 μM for 24 h, inducing apoptosis, attenuating AKT phosphorylation, reducing β-catenin and MMP2 expression, and increasing ERK phosphorylation^[1].
Olitigaltin (10 μM; 24-48 h) attenuates SREBP1 mRNA expression in a time-dependent manner in both BHT-101 and FTC-133 thyroid cancer cells, likely independent of AKT phosphorylation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

FTC-133 human thyroid cancer cells, 8505C human thyroid cancer cells, Nthy-ori 3-1 human thyroid follicular epithelial cells
Concentration:

10-100 μM
Incubation Time:

24-72 h
Result:

Reduced cell viability in FTC-133 and 8505C thyroid cancer cells in a dose-dependent manner.
Reduced cell viability by 41% in FTC-133 cells and 49% in 8505C cells at 100 μM for 72 h.
Did not affect cell viability in Nthy-ori 3-1 non-transformed thyroid follicular epithelial cells.

Cell Cycle Analysis^[1]

Cell Line:

FTC-133 human thyroid cancer cells, 8505C human thyroid cancer cells
Concentration:

10-100 μM
Incubation Time:

24 h
Result:

Increased the percentage of sub-G1 cells to 31% in FTC-133 cells and 35% in 8505C cells at 100 μM for 24 h.
Decreased the percentage of S-phase cells in both cell lines at 100 μM for 24 h.

Western Blot Analysis^[1]

Cell Line:

FTC-133 human thyroid cancer cells, 8505C human thyroid cancer cells
Concentration:

10-100 μM
Incubation Time:

24 h
Result:

Did not alter galectin-3 expression in either cell line.
Reduced cyclin D1 expression, increased cleaved caspase-3 expression, and induced PARP1 cleavage at 100 μM for 24 h.
Increased ERK phosphorylation, did not affect p38 MAPK phosphorylation, attenuated AKT phosphorylation, decreased β-catenin expression, and reduced MMP2 expression in both cell lines.

Real Time qPCR^[3]

Cell Line:

human thyroid cancer cell lines BHT-101 (BRAF V600E mutant), FTC-133 (wild-type BRAF)
Concentration:

10 μM
Incubation Time:

24-48 h
Result:

Reduced SREBF1a and SREBF1c transcript levels in a time-dependent manner in both BHT-101 and FTC-133 cells.
Caused a substantial decrease in SREBF1a and SREBF1c mRNA after 48 h in BHT-101 cells.
Caused a moderate decrease in SREBF1a and SREBF1c mRNA after 48 h in FTC-133 cells.

In Vivo

Olitigaltin (10 mg; i.t.; 4 doses (Days 18, 20, 22, 24 post-bleomycin instillation)) attenuates late-stage Bleomycin (HY-17565A)-induced lung fibrosis in female C57/Bl6 mice, reducing total lung collagen content and histologic fibrosis score while inhibiting β-catenin activation^[2].
Olitigaltin (15 mg/kg; i.p.; daily; 8 weeks) delays diabetes onset, reduces diabetes incidence to 20.0% by 30 weeks of age, improves glucose tolerance and pancreatic β cell function, and modulates islet immune cell populations in female NOD mice with spontaneous type 1 diabetes^[4].
Olitigaltin (15 mg/kg; i.p.; once daily; 7 days) mitigates LPS-induced neuroinflammation, preserves excitatory synapses, restores hippocampal gamma oscillations, and improves cognitive function in male C57BL/6J mice^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57/Bl6 (female; bleomycin-induced lung fibrosis model)^[2]
Dosage:

10 mg
Administration:

i.t.; 4 doses (Days 18, 20, 22, 24 post-bleomycin instillation)
Result:

Reduced total lung collagen content from 472 μg per lung to 304 μg per lung.
Decreased histologic fibrosis score from 3.8 to 2.6.
Reduced nuclear staining of active β-catenin in lung tissue.
Markedly reduced lung fibrosis, β-catenin activation, and galectin-3 expression compared to bleomycin-only controls.

Animal Model:

NOD mice (female, 4 weeks old)^[4]
Dosage:

15 mg/kg
Administration:

i.p.; daily; 8 weeks
Result:

Delayed diabetes onset to ~21 weeks of age.
Reduced diabetes incidence to 20.0% at 30 weeks of age.
Improved glucose tolerance.
Increased serum insulin levels at 0 and 15 minutes during intraperitoneal glucose tolerance test.
Attenuated pancreatic immune cell infiltration and β cell destruction.
Increased the frequency of CD4+CD25+FOXP3+ T_reg cells in pancreatic islets.
Reduced perforin secretion capacity and Tc1 (CD8+IFN-γ+) cell frequency in islet CD8+ T cells.

Animal Model:

C57BL/6J (male, 8-10 weeks old, LPS-induced neuroinflammation)^[6]
Dosage:

15 mg/kg
Administration:

i.p.; once daily
Result:

Reversed LPS-induced reduction in Y-maze spontaneous alternation percentage and restored the novel object recognition discrimination index toward control levels.
Suppressed LPS-induced elevations in hippocampal IL-6, TNF-α, and IL-1β protein levels, and reduced LPS-increased Gal-3 expression, proportion of Gal-3+/Iba1+ microglia, Manders' overlap coefficient between Gal-3 and Iba1, proportion of CD68+/Iba1+ microglia, and CD68 fluorescence intensity.
Restored LPS-reduced relative power in hippocampal CA1 low-gamma and high-gamma bands toward control levels.
Prevented LPS-induced reductions in CA1 pyramidal neuron spine density, dendritic complexity, and densities of VGLUT1+, PSD95+, and VGLUT1+/PSD95+ co-labeled excitatory synaptic puncta, while attenuating LPS-increased volumes of VGLUT1 and PSD95 within Iba1-segmented microglia.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1450824-22-2
Appearance Solid
Molecular Weight 648.64
Formel C₂₈H₃₀F₂N₆O₈S
Color White to off-white
SMILES

O[C@H]([C@@H](N1N=NC(C2=CC=CC(F)=C2)=C1)[C@H]([C@@H](CO)O3)O)[C@@H]3S[C@H]4[C@@H]([C@@H](N5N=NC(C6=CC=CC(F)=C6)=C5)[C@H]([C@@H](CO)O4)O)O
Synonyms

TD139; GB0139
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (13)

All ELISART-PCRWBIFIn Vivo Imaging

Sort by:

Journal Impact Factor

Autophagy

LGALS3 (galectin 3) mediates an unconventional secretion of SNCA/α-synuclein in response to lysosomal membrane damage by the autophagic-lysosomal pathway in human midbrain dopamine neurons. [Abstract]

2022 May;18(5):1020-1048. PMID: 34612142

Olitigaltin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 May;18(5):1020-1048. [Abstract]

Relative fold difference in SNCA from mDA cultured media treated with Olitigaltin (TD139) (5 μM) or vehicle (0.1% DMSO) treated control after 24 h measured by ELISA. The results showed that TD139 treatment significantly reduced SNCA secretion compared to vehicle.

Olitigaltin purchased from MedChemExpress. Usage Cited in: Autophagy. 2022 May;18(5):1020-1048. [Abstract]

Representative non-reducing SDS-PAGE of concentrated EVs and the corresponding lysates from mDA neurons treated with vehicle, Olitigaltin (TD139, 1 µM; 24 h), SNCA fibrils, or TD139 + SNCA fibrils.
J Neuroinflammation

Genetic targeting or pharmacological inhibition of galectin-3 dampens microglia reactivity and delays retinal degeneration. [Abstract]

2022 Sep 17;19(1):229. PMID: 36115971

Olitigaltin purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2022 Sep 17;19(1):229. [Abstract]

Relative mRNA expression of pro-inflammatory cytokines in retinas of naïve and light-exposed mice treated with vehicle or Olitigaltin (TD139, 15 mg/kg; i.p.; once daily) normalized to the reference gene Atp5b. The results showed that following treatment with TD139, the expression levels of iNOS, IL-6, and CCL2—induced by light damage—were also reduced.

Olitigaltin purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2022 Sep 17;19(1):229. [Abstract]

Olitigaltin (TD139, 15 mg/kg; i.p.; once daily) reduced microglia migration in light-exposed retinas. Representative images of Iba-1⁺ cells in naïve and light-exposed mice treated with vehicle or TD139 at the indicated time points. Scale bar: 50 µm. ONL, outer nuclear layer and INL, inner nuclear layer.

Olitigaltin purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2022 Sep 17;19(1):229. [Abstract]

Olitigaltin (TD139, 15 mg/kg; i.p.; once daily) delayed light-induced retinal degeneration. Representative SD-OCT scans and heat maps of retinal thickness from naïve and light-exposed mice treated with vehicle or TD139. Scale bar: 200 µm.
Stem Cell Res Ther

Mesenchymal stem cells ameliorate renal fibrosis by galectin-3/Akt/GSK3β/Snail signaling pathway in adenine-induced nephropathy rat. [Abstract]

2021 Jul 16;12(1):409. PMID: 34271976
Chem Biol Interact

Inhibition of Galectin-3 attenuates silica particles-induced silicosis via regulating the GSK-3β/β-catenin signal pathway-mediated epithelial-mesenchymal transition. [Abstract]

2022 Dec 1:368:110218. PMID: 36223831
Exp Neurol

Role of galectin-3 in cardiac dysfunction induced by subarachnoid hemorrhage. [Abstract]

2023 Jul:365:114418. PMID: 37085003
Cell Signal

Secretory Galectin-3 promotes hepatic steatosis via regulation of the PPARγ/CD36 signaling pathway. [Abstract]

2021 Aug:84:110043. PMID: 33991615
J Immunol

Gasdermin D Drives the Nonexosomal Secretion of Galectin-3, an Insulin Signal Antagonist. [Abstract]

2019 Nov 15;203(10):2712-2723. PMID: 31597705
Glycobiology

Galectin-3 facilitates helicobacter pylori-induced apoptosis independently of sensing lysosomal damage. [Abstract]

2025 Nov 24:cwaf081. PMID: 41283852
Brain Res

Galectin-3 in microglia mediates neuroinflammation-induced cognitive dysfunction via selective elimination of excitatory synapses in hippocampal CA1. [Abstract]

2026 Sep 15:1887:150382. PMID: 42114797
Patent

US20230273213A1.
Patent

US20220380473A1.
Universität zu Köln

2022 Feb 9.
Patent

US20220002420A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (77.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5417 mL

7.7084 mL

15.4169 mL

5 mM

0.3083 mL

1.5417 mL

3.0834 mL

10 mM

0.1542 mL

0.7708 mL

1.5417 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% HP-β-CD in Saline water

Solubility: 3.33 mg/mL (5.13 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 45% PEG300 5% Tween-80 50% Saline

Solubility: 10 mg/mL (15.42 mM); Clear solution; Need ultrasonic

Protocol 3

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 2 mg/mL (3.08 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (307 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lee JJ, et al. Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells. International journal of endocrinology. 2021;2021:5583491. [Content Brief]

[2]. Mackinnon AC, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. American journal of respiratory and critical care medicine. 2012 Mar 01;185(5):537-46. [Content Brief]

[3]. Huang TS, et al. Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells. Anticancer research. 2022 May;42(5):2487-2493.

[4]. Xie L, et al. Galectin-3 exacerbates autoimmune diabetes by limiting regulatory T cell differentiation and function. Science advances. 2026 Jan 02;12(1):eadz7916.

[5]. Volarevic V, et al. Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology (Baltimore, Md.). 2012 Jun;55(6):1954-64. [Content Brief]

[6]. Wu HP, et al. Galectin-3 in microglia mediates neuroinflammation-induced cognitive dysfunction via selective elimination of excitatory synapses in hippocampal CA1. Brain research. 2026 Sep 15;1887:150382. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5417 mL	7.7084 mL	15.4169 mL	38.5422 mL
	5 mM	0.3083 mL	1.5417 mL	3.0834 mL	7.7084 mL
	10 mM	0.1542 mL	0.7708 mL	1.5417 mL	3.8542 mL
	15 mM	0.1028 mL	0.5139 mL	1.0278 mL	2.5695 mL
	20 mM	0.0771 mL	0.3854 mL	0.7708 mL	1.9271 mL
	25 mM	0.0617 mL	0.3083 mL	0.6167 mL	1.5417 mL
	30 mM	0.0514 mL	0.2569 mL	0.5139 mL	1.2847 mL
	40 mM	0.0385 mL	0.1927 mL	0.3854 mL	0.9636 mL
	50 mM	0.0308 mL	0.1542 mL	0.3083 mL	0.7708 mL
	60 mM	0.0257 mL	0.1285 mL	0.2569 mL	0.6424 mL

Bioz

Olitigaltin

13 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Olitigaltin

GB1107

Thiodigalactoside

Selvigaltin

OTX008

DAPT

MCC950

Rapamycin

Erastin

Tamoxifen

H2DCFDA

Retinoic acid

PLX5622

Publications Citing Use of MedChemExpress (MCE) Olitigaltin

Alle Galectin Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Olitigaltin

GB1107

Thiodigalactoside

Selvigaltin

OTX008

DAPT

MCC950

Rapamycin

Erastin

Tamoxifen

H2DCFDA

Retinoic acid

PLX5622

Publications Citing Use of MedChemExpress (MCE) Olitigaltin

Alle Galectin Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Olitigaltin Related Classifications

HY-19940 Related Classifications

Bioz